Ovarian Cancer Biomarkers: Moving Forward in Early Detection

被引：78
作者：
Bonifacio, Vasco D. B. [1 ]
机构：
[1] Univ Lisbon, Inst Super Tecn, IBB Inst Bioengn & Biosci, Lisbon, Portugal
来源：
TUMOR MICROENVIRONMENT: THE MAIN DRIVER OF METABOLIC ADAPTATION | 2020年 / 1219卷
关键词：
Cancer biomarkers; Ovarian cancer; Early detection; Urine biomarkers; Proteomics; Metabolomics; FOLLOW-UP; SERUM; IDENTIFICATION; PROTEOMICS; PROTEIN; URINE; CA125; DISCOVERY; MARKER; ALPHA;
D O I：
10.1007/978-3-030-34025-4_18
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Ovarian cancer is a silent cancer which rate survival mainly relays in early stage detection. The discovery of reliable ovarian cancer biomarkers plays a crucial role in the disease management and strongly impact in patient's prognosis and survival. Although having many limitations CA125 is a classical ovarian cancer biomarker, but current research using proteomic or metabolomic methodologies struggles to find alternative biomarkers, using non-invasive our relatively non-invasive sources such as urine, serum, plasma, tissue, ascites or exosomes. Metabolism and metabolites are key players in cancer biology and its importance in biomarkers discovery cannot be neglected. In this chapter we overview the state of art and the challenges facing the use and discovery of biomarkers and focus on ovarian cancer early detection.
引用
收藏
页码：355 / 363
页数：9
相关论文
共 81 条
[1]   Proteomic tracking of serum protein isoforms as screening biomarkers of ovarian cancer [J].
Ahmed, N ;
Oliva, KT ;
Barker, G ;
Hoffmann, P ;
Reeve, S ;
Smith, IA ;
Quinn, MA ;
Rice, GE .
PROTEOMICS, 2005, 5 (17) :4625-4636
[2]   Proteomic-based identification of haptoglobin-1 precursor as a novel circulating biomarker of ovarian cancer [J].
Ahmed, N ;
Barker, G ;
Oliva, KT ;
Hoffmann, P ;
Riley, C ;
Reeve, S ;
Smith, AL ;
Kemp, BE ;
Quinn, MA ;
Rice, GE .
BRITISH JOURNAL OF CANCER, 2004, 91 (01) :129-140
[3]  
Akinyemiju T., 2018, ONCOTARGET, V9, P16099, DOI [10.18632/oncotarget.24559, DOI 10.18632/ONCOTARGET.24559]
[4]   Comparative proteomics of ovarian epithelial tumors [J].
An, HJ ;
Kim, DS ;
Park, YK ;
Kim, SK ;
Choi, YP ;
Kang, S ;
Ding, BX ;
Cho, NH .
JOURNAL OF PROTEOME RESEARCH, 2006, 5 (05) :1082-1090
[5]   Urinary levels of Bcl-2 are elevated in ovarian cancer patients [J].
Anderson, Nicole S. ;
Bermudez, Yira ;
Badgwell, Donna ;
Chen, Ren ;
Nicosia, Santo V. ;
Bast, Robert C., Jr. ;
Kruk, Patricia A. .
GYNECOLOGIC ONCOLOGY, 2009, 112 (01) :60-67
[6]   The human plasma proteome - History, character, and diagnostic prospects [J].
Anderson, NL ;
Anderson, NG .
MOLECULAR & CELLULAR PROTEOMICS, 2002, 1 (11) :845-867
[7]   Urinary mesothelin provides greater sensitivity for early stage ovarian cancer than serum mesothelin, urinary hCG free beta subunit and urinary hCG beta core fragment [J].
Badgwell, Donna ;
Lu, Zhen ;
Cole, Laurence ;
Fritsche, Herbert ;
Atkinson, Edward N. ;
Somers, Elizabeth ;
Allard, Jeffrey ;
Moore, Richard G. ;
Lu, Karen H. ;
Bast, Robert C., Jr. .
GYNECOLOGIC ONCOLOGY, 2007, 106 (03) :490-497
[8]   CA 125: The past and the future [J].
Bast, RC ;
Xu, FJ ;
Yu, YH ;
Barnhill, S ;
Zhang, Z ;
Mills, GB .
INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 1998, 13 (04) :179-187
[9]  
Bergen HR, 2003, DIS MARKERS, V19, P239
[10]   Metabolomic characterization of experimental ovarian cancer ascitic fluid [J].
Bharti, Santosh K. ;
Wildes, Flonne ;
Hung, Chien-Fu ;
Wu, T. C. ;
Bhujwalla, Zaver M. ;
Penet, Marie-France .
METABOLOMICS, 2017, 13 (10)
123456789